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See Article, pages 486–492Ribavirin is a key antiviral component in the treatment of hepa-
titis C virus (HCV) infection. Although it is only minimally effec-
tive as a monotherapeutic agent [2,7], in combination with
Interferon it increases the sustained virological response rate
(SVR) upon antiviral treatment compared to Interferon alone
from 13% to 40% [11]. Thus, the combination therapy with Riba-
virin and Interferon is currently recommended for the treatment
of chronic HCV infection. Of note, high doses of Ribavirin and the
presence of Ribavirin-associated side effects (e.g., anemia) are
positive predictors of SVR, underlining the pivotal role of Ribavi-
rin in the success of the combination therapy [10,12]. New anti-
viral therapies speciﬁcally targeted to HCV will further improve
treatment success rates but a combination with Ribavirin will
most likely continue to be required to reduce viral relapse and
increase SVR [6,9].
Despite the clear effectivity of Ribavirin in the treatment of
chronic HCV infection, the underlying mechanisms of action are
still unclear. Ribavirin is a purine nucleoside analog that is struc-
turally related to Guanosine [3]. It is converted to Ribavirinmono-
phosphat (RMP) and Ribavirintriphosphat intracellularly (RTP).
Four potential mechanisms of Ribavirin’s anti-HCV activity have
been suggested [3,4] (Fig. 1): ﬁrst, direct inhibition of HCV RNA
replication due to the erroneous incorporation of RTP into repli-
cating RNA strands by viral polymerases. Second, increase of
HCV mutagenesis to the level of error catastrophe. Third, inhibi-
tion of the host enzyme inosine monophosphate dehydrogenase
(IMPDH) required for GTP synthesis. Fourth, immunomodulation
resulting in a stronger antiviral T cell response. These hypotheses
are derived mainly from in vitro data that support each of the pro-
posed mechanisms. However, it is unclear how Ribavirin exerts
its anti-HCV activity in vivo and why it is only effective in combi-
nation therapy with Interferon [3].
It is reasonable to assume that the uptake of Ribavirin into
virus-infected hepatocytes is a prerequisite for its antiviral activ-
ity. In addition, the level of Ribavirin uptake may deﬁne its anti-
viral effectivity and thus, differences in Ribavirin uptake may
account for differential treatment outcomes. However, there is
limited data available regarding Ribavirin uptake in human
hepatocytes.
Synthetic nucleosides such as Ribavirin can be imported into
the cell by nucleoside transporters, that can be classiﬁed intoJournal of Hepatology 20
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4) are proteins that facilitate the bidirectional diffusion of nucle-
otides across the cell membrane in a concentration-dependent
manner, whereas concentrative nucleoside transporters (e.g.,
CNT1–3) use the Na+-gradient as a driving force to import nucleo-
sides against a concentration gradient. Previous studies in animal
cell lines and immortalized human hepatoma cells have shown
that Ribavirin may be potentially transported into host cells by
ENT1, ENT2, CNT2 and CNT3 [8,13]. It was unclear, however,
which of the transporters are responsible for the import of Riba-
virin into human hepatocytes.
A study published in this issue of the Journal of Hepatology
addresses this important question. Fukuchi et al. analyzed the
contribution of putative Ribavirin transporters in human hepato-
cytes derived from three deceased donors without underlying
liver disease [5]. For the functional analyses, the authors used
radioactive-labeled Ribavirin uptake assays in the presence or
absence of the ENT inhibitor nitrobenzylmercaptopurine riboside
(NBMPR) and in Na+-containing and Na+-free buffers. They found
that Ribavirin uptake is primarily mediated by a Na+-indepen-
dent, NBMPR-sensitive system that shows the typical characteris-
tics of ENT1. Next, they analyzed the mRNA expression of
putative Ribavirin transporters. Indeed, ENT1 was also found to
be expressed in all human hepatocytes analyzed, and high levels
of ENT1 expression in hepatocytes correlated with high Ribavirin
uptake rates, underlining the major role of ENT1 in mediating
Ribavirin uptake. In contrast, ENT2, which was also expressed
in human hepatocytes, did not mediate Ribavirin uptake in the
hepatocytes nor in control hepatoma cells that overexpressed
ENT2. This was an unexpected ﬁnding since previous reports
had shown an ENT2-mediated Ribavirin uptake in Xenopus
oocytes [13]. The Na+-dependent CNT2 and CNT3 transporters
were expressed only at lower levels compared to ENT1 and
ENT2. Although the contribution of Na+-dependent Ribavirin
uptake was neglectable compared to ENT1 in two out of three
hepatocyte donors analyzed in this study, in hepatocytes derived
from one particular donor, 27–43% of Ribavirin uptake was Na+-
dependent. Hence, Fukuchi et al. cannot exclude the possibility
that Na+-dependent transporters, such as CNT2 and CNT3 or yet
unidentiﬁed additional Ribavirin transporters may contribute to
substantial amounts of Ribavirin uptake in some individuals. In
summary, using an experimental system that closely mimicks
the in vivo situation, Fukuchi et al. demonstrate that ENT1 is
the major Ribavirin uptake transporter in human hepatocytes.10 vol. 52 j 469–471
Fig. 1. The putative antiviral mechanisms of action of Ribavirin during the treatment of HCV infection. Upon Ribavirin uptake into hepatocytes through the ENT1
transporter, it gets modiﬁed by cellular kinases to RMP and RTP. RTP causes enhanced HCV mutagenesis due to erroneous integration of RTP into newly synthesized viral
RNA and may also directly inhibit HCV replication. RMP inhibits IMPDH which converts IMP to GTP, thus effectively depleting the intracellular GTP pool required for viral
replication. In addition, Ribavirin treatment may enhance the antiviral T cell function. TH, T helper cells; RdRp, RNA-dependent RNA polymerase.
EditorialIn an attempt to understand why ENT1 expression levels var-
ied among the donor cells, the authors analyzed the 50 region of
the SLC29A1 gene which codes for ENT1. Interestingly, by analyz-
ing human liver cDNA with the RLM-50-RACE technique, Fukuchi
et al. identiﬁed four alternative promoter regions (P1, P2.1, P2.2
and P3) that regulate SLC29A1 gene transcription and generate
at least 12 ENT1 mRNA isoforms. The authors then analyzed
which ENT1 isoforms were expressed by human hepatocytes
and found that the majority of ENT1 mRNAs was dependent on
the P3 promoter region. Importantly, the expression of these
mRNA isoforms (named ENT1 d1–4) also correlated with
increased Ribavirin uptake of donor hepatocytes. These results
demonstrate the existence of multiple ENT1 mRNA isoforms in
human hepatocytes that may potentially explain differences in
Ribavirin uptake by hepatocytes and might thus inﬂuence the
outcome of antiviral therapy in chronic HCV patients.
In agreement with this hypothesis, a reduced Ribavirin antivi-
ral efﬁcacy against a model RNA virus was recently found to be
associated with a reduced Ribavirin uptake in Ribavirin resistant
cell lines [8]. Importantly, the Ribavirin resistance in this model
could be overcome by ENT1 overexpression, indicating that alter-
ations in the expression of Ribavirin transporters may confer
resistance to antiviral therapy [8]. It is tempting to speculate that
a similar mechanism might be active during the treatment of
chronic HCV patients with Ribavirin. However, until now the role
of Ribavirin transporters has not been addressed in HCV-infected
hepatocytes. The recent establishment of infectious replicating
HCV cell culture systems [1] may provide the adequate tools
for future and more precise analyses of the anti-HCVmechanisms
exerted by Ribavirin.
Fukuchi et al. have clariﬁed that ENT1 is the major Ribavirin
transporter in human hepatocytes. Furthermore, they have
showed that ENT1 expression is regulated by at least four pro-470 Journal of Hepatology 201moter regions, that multiple ENT1 mRNA isoforms can be
detected in human hepatocytes, and that speciﬁc ENT1 isoforms
correlate with Ribavirin uptake. These are important new insights
leading to additional questions that will have to be addressed in
the future, e.g., whether the different ENT1 mRNA isoforms
indeed translate into differences in ENT1 transporter function
and how ENT1 mRNA isoform expression is regulated. Since
Fukuchi et al. have analyzed Ribavirin uptake in human hepato-
cytes from non-HCV infected donors, it also remains unclear
whether the expression of Ribavirin transporters is altered by
HCV infection and whether Ribavirin transporters are inﬂuenced
by Interferon and Ribavirin treatment.
Clearly, the identiﬁcation of the major Ribavirin uptake trans-
porter in human hepatocytes is an important step towards a con-
clusive answer to the puzzling enigma of the mechanism of
action of Ribavirin in the treatment of HCV infection.References
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